Abstract
Background
Anaplastic thyroid carcinoma (ATC) is a rare but the most aggressive type of thyroid carcinoma. Nevertheless, limited advances were made to reduce mortality and improve survival over the last decades. Therefore, identifying novel diagnostic biomarkers and therapeutic targets for ATC patients is still needed.
Materials and methods
RNA sequencing data and corresponding clinical features were available from GEO and TCGA databases. We integrated WGCNA and PPI network analysis to identify hub genes associated with ATC development, and RT-qPCR was employed for data verification. Univariate and LASSO Cox regression analyses were used to generate prognostic signatures.
Results
Based on PPI and WGCNA, 6 hub genes were identified, namely KIF2C, PBK, TOP2A, CDK1, KIF20A, and ASPM, which play vital roles in ATC development. Subsequently, RT-qPCR experiments showed that most of these genes were significantly upregulated in CAL-62 cells compared to Nthy-ori 3–1 cells. Moreover, a prognostic signature featuring GPSM2, FGF5, ASXL3, CYP4B1, CLMP, and DUXAP9 was generated, which was also verified by RT-qPCR results and proved as an independent predictor of poorer prognosis of ATC. Additionally, a nomogram incorporating the risk score and clinicopathological parameters was further constructed for accurate prediction of 1-, 3- and 5-year survival probabilities of ATC.
Conclusions
Our study identified 6 key genes critical to ATC development and constructed a prognostic signature. These findings provide reliable biomarkers and a relatively comprehensive tumorigenesis profile of ATC, which may inform future strategies for clinical diagnosis and pharmaceutical design.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 920th Hospitalof Joint Logistics Support Force of People’s Liberation Army, Department of Clinical Pharmacy, Kunming, China; Dali University, College of Pharmacy, Dali, China (GRID:grid.440682.c) (ISNI:0000 0001 1866 919X)
2 920th Hospital of JointLogistics Support Force of People’s Liberation Army, Department of Pathology, Kunming, China (GRID:grid.440682.c)
3 Kunming Tongren Hospital, Oncology Department, Kunming, China (GRID:grid.490275.d)
4 920th Hospitalof Joint Logistics Support Force of People’s Liberation Army, Department of Clinical Pharmacy, Kunming, China (GRID:grid.490275.d); Dali University, College of Pharmacy, Dali, China (GRID:grid.440682.c) (ISNI:0000 0001 1866 919X)
5 920th Hospitalof Joint Logistics Support Force of People’s Liberation Army, Department of Clinical Pharmacy, Kunming, China (GRID:grid.440682.c)
6 920th Hospitalof Joint Logistics Support Force of People’s Liberation Army, Department of Clinical Pharmacy, Kunming, China (GRID:grid.440682.c); Dali University, College of Pharmacy, Dali, China (GRID:grid.440682.c) (ISNI:0000 0001 1866 919X)
7 Dali University, College of Pharmacy, Dali, China (GRID:grid.440682.c) (ISNI:0000 0001 1866 919X)
8 The 306th Hospital of People’s LiberationArmy (PLA), Medical Engineering Section, Beijing, China (GRID:grid.413138.c)
9 920th Hospitalof Joint Logistics Support Force of People’s Liberation Army, Department of Clinical Pharmacy, Kunming, China (GRID:grid.413138.c)




